[go: up one dir, main page]

UA110118C2 - Мікобактеріальна антигенна композиція - Google Patents

Мікобактеріальна антигенна композиція

Info

Publication number
UA110118C2
UA110118C2 UAA201306355A UAA201306355A UA110118C2 UA 110118 C2 UA110118 C2 UA 110118C2 UA A201306355 A UAA201306355 A UA A201306355A UA A201306355 A UAA201306355 A UA A201306355A UA 110118 C2 UA110118 C2 UA 110118C2
Authority
UA
Ukraine
Prior art keywords
antigen composition
mycobacterial antigen
composition
sequence
related antigen
Prior art date
Application number
UAA201306355A
Other languages
English (en)
Russian (ru)
Inventor
Стефан Андре Ґеорґес Ґодарт
Аміна Ланан
Домінік Інґрід Лемоін
Original Assignee
Ґлаксосмітклайн Байолоджікалз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ґлаксосмітклайн Байолоджікалз С.А. filed Critical Ґлаксосмітклайн Байолоджікалз С.А.
Publication of UA110118C2 publication Critical patent/UA110118C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується імуногенної композиції, яка містить антиген, споріднений з М72, де антиген, споріднений з М72, включає послідовність, що має принаймні 90 % ідентичності з послідовністю SEQ ID No: 1, та рН вказаної композиції лежить в інтервалі від 7,0 до 9,0, а електропровідність композиції складає 5 мСм/см або менше.
UAA201306355A 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція UA110118C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14
PCT/EP2011/072816 WO2012080369A1 (en) 2010-12-14 2011-12-14 Mycobacterium antigenic composition

Publications (1)

Publication Number Publication Date
UA110118C2 true UA110118C2 (uk) 2015-11-25

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201306356A UA110806C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція
UAA201306355A UA110118C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201306356A UA110806C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція

Country Status (33)

Country Link
US (5) US9730992B2 (uk)
EP (4) EP3023106B1 (uk)
JP (2) JP5951633B2 (uk)
KR (3) KR20190022897A (uk)
CN (4) CN106822883A (uk)
AR (1) AR084285A1 (uk)
AU (2) AU2011343368C1 (uk)
BR (2) BR112013014599A2 (uk)
CA (2) CA2819297A1 (uk)
CO (2) CO6751288A2 (uk)
CY (1) CY1122187T1 (uk)
DK (3) DK2651436T3 (uk)
EA (2) EA027920B1 (uk)
ES (3) ES2574403T3 (uk)
HR (3) HRP20160362T1 (uk)
HU (3) HUE028452T2 (uk)
IL (2) IL226448A (uk)
LT (1) LT3023106T (uk)
ME (1) ME02380B (uk)
MX (2) MX344280B (uk)
MY (1) MY161412A (uk)
PH (2) PH12013501204A1 (uk)
PL (3) PL3023106T3 (uk)
PT (2) PT2651436E (uk)
RS (1) RS54687B1 (uk)
SG (2) SG190937A1 (uk)
SI (3) SI3023106T1 (uk)
SM (1) SMT201600118B (uk)
TW (1) TW201305192A (uk)
UA (2) UA110806C2 (uk)
UY (1) UY33802A (uk)
WO (2) WO2012080370A1 (uk)
ZA (2) ZA201304015B (uk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877426B1 (en) 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
KR20190022897A (ko) * 2010-12-14 2019-03-06 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
MX341918B (es) 2011-01-04 2016-09-07 Archivel Farma Sl Formulación de liposomas adecuada para tratar o prevenir la tuberculosis.
US9682042B2 (en) 2012-01-12 2017-06-20 Archivel Farma, S.L. MTB-C vaccine against asthma
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals Sa métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
KR20210038919A (ko) 2018-07-31 2021-04-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 정제 방법
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
BR112022004228A2 (pt) 2019-09-09 2022-05-31 Glaxosmithkline Biologicals Sa Composições imunoterapêuticas
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112022020660A2 (pt) 2020-05-05 2022-11-29 Glaxosmithkline Biologicals Sa Dispositivo de mistura microfluídica e métodos de uso
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
WO2022122830A2 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69636075D1 (de) 1995-09-01 2006-06-01 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
PT1203817E (pt) 1995-09-01 2006-08-31 Corixa Corp Compostos e metodos para imunoterapia e le diagnostic de tuberculose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
DK0973546T3 (da) * 1997-04-08 2004-06-28 Merck & Co Inc Stabiliserede formuleringer med human papillomavirus
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CZ302870B6 (cs) * 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
KR20010042573A (ko) * 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
CA2386841A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU6867801A (en) 2000-06-20 2002-01-02 Corixa Corp Fusion proteins of mycobacterium tuberculosis
SI1296715T2 (sl) 2000-06-29 2016-03-31 Smithkline Beecham Biologicals S.A. Multivalentni sestavek cepiva
WO2003070187A2 (en) * 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1877426B1 (en) * 2005-04-29 2012-02-01 GlaxoSmithKline Biologicals SA Method for preventing or treating m tuberculosis infection
EP2087128A4 (en) 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
UY31101A1 (es) 2007-05-24 2009-01-05 Glaxosmithkline Biologicals Sa Composición antigénica liofilizada
KR20150080038A (ko) 2007-11-30 2015-07-08 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
KR100955470B1 (ko) 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
WO2009111874A1 (en) 2008-03-11 2009-09-17 The Royal Institution For The Advancement Of Learning/ Mcgiil University Low-temperature wafer level processing for mems devices
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
KR20190022897A (ko) 2010-12-14 2019-03-06 글락소스미스클라인 바이오로지칼즈 에스.에이. 미코박테리움 항원성 조성물
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
HUE027932T2 (en) 2016-11-28
UY33802A (es) 2012-07-31
ES2567190T3 (es) 2016-04-20
IL226448A0 (en) 2013-07-31
SI2651436T1 (sl) 2016-07-29
US20130287809A1 (en) 2013-10-31
EP2651437A1 (en) 2013-10-23
ES2748651T3 (es) 2020-03-17
EA027504B1 (ru) 2017-08-31
AU2011343368C1 (en) 2015-12-24
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
PL2651436T3 (pl) 2016-10-31
EP2651436A1 (en) 2013-10-23
CY1122187T1 (el) 2020-11-25
BR112013014599A2 (pt) 2016-09-27
KR101951894B1 (ko) 2019-02-26
ZA201304014B (en) 2017-04-26
EP3593813A1 (en) 2020-01-15
TW201305192A (zh) 2013-02-01
EP3023106A1 (en) 2016-05-25
MX2013006818A (es) 2013-08-26
PT2651436E (pt) 2016-06-08
IL226450A0 (en) 2013-07-31
MX2013006819A (es) 2013-08-26
KR20190022897A (ko) 2019-03-06
CN103249431B (zh) 2016-11-02
CN103249431A (zh) 2013-08-14
DK2651436T3 (da) 2016-06-20
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
PT3023106T (pt) 2019-11-04
CO6751287A2 (es) 2013-09-16
US9730992B2 (en) 2017-08-15
ZA201304015B (en) 2018-12-19
SMT201600118B (it) 2016-07-01
US20160220656A1 (en) 2016-08-04
CN103260642B (zh) 2018-03-16
HUE028452T2 (en) 2016-12-28
EP2651436B1 (en) 2016-03-30
LT3023106T (lt) 2019-10-25
SI2651437T1 (sl) 2016-05-31
AU2011343368B2 (en) 2015-08-20
ES2574403T3 (es) 2016-06-17
WO2012080369A1 (en) 2012-06-21
MX344280B (es) 2016-12-09
EA201390631A1 (ru) 2014-11-28
SG190731A1 (en) 2013-07-31
JP2013545783A (ja) 2013-12-26
US9352030B2 (en) 2016-05-31
AU2011343367A1 (en) 2013-07-11
WO2012080370A1 (en) 2012-06-21
AU2011343368A1 (en) 2013-07-11
JP2014505036A (ja) 2014-02-27
DK2651437T3 (en) 2016-05-02
BR112013014598A2 (pt) 2017-09-19
SI3023106T1 (sl) 2019-11-29
KR20140029376A (ko) 2014-03-10
CN103260642A (zh) 2013-08-21
EA201390630A1 (ru) 2013-12-30
CA2819297A1 (en) 2012-06-21
PH12013501204A1 (en) 2013-07-29
MY161412A (en) 2017-04-14
EA027920B1 (ru) 2017-09-29
IL226448A (en) 2017-09-28
EP3023106B1 (en) 2019-07-31
CA2819298A1 (en) 2012-06-21
PH12013501203A1 (en) 2013-07-29
PL3023106T3 (pl) 2019-12-31
UA110806C2 (uk) 2016-02-25
MX344706B (es) 2017-01-03
HRP20160606T1 (hr) 2016-07-01
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
KR20130124525A (ko) 2013-11-14
EP2651437B1 (en) 2016-02-10
SG190937A1 (en) 2013-07-31
JP5951634B2 (ja) 2016-07-13
CO6751288A2 (es) 2013-09-16
CN106822883A (zh) 2017-06-13
US20130280289A1 (en) 2013-10-24
US20190183998A1 (en) 2019-06-20
AU2011343367B2 (en) 2015-05-21
JP5951633B2 (ja) 2016-07-13
HRP20191843T1 (hr) 2019-12-27
DK3023106T3 (da) 2019-09-30
US20180071378A1 (en) 2018-03-15
PL2651437T3 (pl) 2016-07-29
RS54687B1 (sr) 2016-08-31

Similar Documents

Publication Publication Date Title
UA110118C2 (uk) Мікобактеріальна антигенна композиція
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EA201000327A1 (ru) Белок
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
EP4230644A3 (en) Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
PH12012500849A1 (en) Mycobacterial vaccines
NZ703378A (en) Degradable clostridial toxins
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX349630B (es) Alfa-amilasas.
MX2020010399A (es) 3-epimerasa.
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
SG195194A1 (en) Nanogels
JO3257B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
MX375202B (es) Composiciones adyuvantes novedosas.
PH12013501636A1 (en) Treatment of osteoarthritis and pain
SG11201806502UA (en) Conjugate of therapeutic enzymes
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
EA201300585A1 (ru) Иммуномодулирующие олигонуклеотиды
MX374291B (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
BR112012024963A2 (pt) organossilicones
EA201300915A1 (ru) Новый европейский штамм prrsv
IN2015MN00436A (uk)
EA201300876A1 (ru) Мутантная целлобиогидролаза
IN2015DN03307A (uk)
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV